$BCYC
Bicycle Therapeutics PLC

2022 Q1 Form 10-Q Financial Statement

#000155837022007223 Filed on May 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $3.860M $1.808M
YoY Change 113.5% 60.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.85M $8.100M
YoY Change 107.98% 62.0%
% of Gross Profit
Research & Development $14.28M $9.693M
YoY Change 47.36% 24.75%
% of Gross Profit
Depreciation & Amortization $422.0K $325.0K
YoY Change 29.85% 4.84%
% of Gross Profit
Operating Expenses $31.24M $17.83M
YoY Change 75.21% 39.64%
Operating Profit -$27.38M -$16.02M
YoY Change 70.89%
Interest Expense $818.0K $522.0K
YoY Change 56.7% 148.57%
% of Operating Profit
Other Income/Expense, Net -$600.0K -$507.0K
YoY Change 18.34%
Pretax Income -$27.98M -$16.53M
YoY Change 69.28% 44.63%
Income Tax -$400.0K -$300.0K
% Of Pretax Income
Net Earnings -$27.56M -$16.19M
YoY Change 70.24% 42.98%
Net Earnings / Revenue -714.09% -895.52%
Basic Earnings Per Share -$0.93 -$0.73
Diluted Earnings Per Share -$0.93 -$0.73
COMMON SHARES
Basic Shares Outstanding 29.61M 22.10M
Diluted Shares Outstanding 29.61M 22.10M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $407.4M $195.9M
YoY Change 107.95% 78.74%
Cash & Equivalents $407.4M $195.9M
Short-Term Investments
Other Short-Term Assets $9.067M $6.000M
YoY Change 51.12% 42.86%
Inventory
Prepaid Expenses
Receivables $0.00 $2.000M
Other Receivables $13.33M $11.50M
Total Short-Term Assets $429.8M $215.4M
YoY Change 99.52% 74.55%
LONG-TERM ASSETS
Property, Plant & Equipment $8.849M $6.300M
YoY Change 40.46% 57.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.198M $2.200M
YoY Change 90.82% 15.79%
Total Long-Term Assets $29.80M $8.400M
YoY Change 254.73% 42.37%
TOTAL ASSETS
Total Short-Term Assets $429.8M $215.4M
Total Long-Term Assets $29.80M $8.400M
Total Assets $459.6M $223.8M
YoY Change 105.35% 73.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.999M $1.000M
YoY Change 299.9% -77.27%
Accrued Expenses $12.27M $9.600M
YoY Change 27.76% 71.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $35.41M $20.80M
YoY Change 70.26% 28.4%
LONG-TERM LIABILITIES
Long-Term Debt $30.01M $29.50M
YoY Change 1.72%
Other Long-Term Liabilities $3.362M $31.40M
YoY Change -89.29% 0.32%
Total Long-Term Liabilities $33.37M $60.90M
YoY Change -45.21% 94.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $35.41M $20.80M
Total Long-Term Liabilities $33.37M $60.90M
Total Liabilities $129.3M $81.80M
YoY Change 58.07% 72.21%
SHAREHOLDERS EQUITY
Retained Earnings -$245.9M
YoY Change
Common Stock $385.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $330.3M $142.1M
YoY Change
Total Liabilities & Shareholders Equity $459.6M $223.8M
YoY Change 105.35% 73.09%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$27.56M -$16.19M
YoY Change 70.24% 42.98%
Depreciation, Depletion And Amortization $422.0K $325.0K
YoY Change 29.85% 4.84%
Cash From Operating Activities -$26.40M -$13.71M
YoY Change 92.6% -164.78%
INVESTING ACTIVITIES
Capital Expenditures $4.756M $623.0K
YoY Change 663.4% -294.69%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$4.756M -$623.0K
YoY Change 663.4% 94.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 450.0K 74.06M
YoY Change -99.39%
NET CHANGE
Cash From Operating Activities -26.40M -13.71M
Cash From Investing Activities -4.756M -623.0K
Cash From Financing Activities 450.0K 74.06M
Net Change In Cash -31.31M 59.91M
YoY Change -152.26% 187.48%
FREE CASH FLOW
Cash From Operating Activities -$26.40M -$13.71M
Capital Expenditures $4.756M $623.0K
Free Cash Flow -$31.16M -$14.33M
YoY Change 117.42% -166.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29605143
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22100840
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001761612
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29605143
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22100840
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29579364
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29644438
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-38916
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Bicycle Therapeutics plc
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
B900
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Babraham Research Campus
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2022Q1 dei Entity Address Country
EntityAddressCountry
GB
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
CB22 3AT
CY2022Q1 dei City Area Code
CityAreaCode
+44
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
1223 261503
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29648534
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
407371000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
438680000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1000000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9067000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7965000
CY2022Q1 bcyc Research And Development Incentives Receivable Current
ResearchAndDevelopmentIncentivesReceivableCurrent
13328000
CY2021Q4 bcyc Research And Development Incentives Receivable Current
ResearchAndDevelopmentIncentivesReceivableCurrent
10910000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
429766000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
458555000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8849000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3123000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16750000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14666000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4198000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3448000
CY2022Q1 us-gaap Assets
Assets
459563000
CY2021Q4 us-gaap Assets
Assets
479792000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3999000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2721000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12265000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14244000
CY2022Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19150000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19273000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
35414000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36238000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
30008000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29873000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14093000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12081000
CY2022Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
46428000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
52067000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3362000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3279000
CY2022Q1 us-gaap Liabilities
Liabilities
129305000
CY2021Q4 us-gaap Liabilities
Liabilities
133538000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
57070181
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
55295420
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29644438
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29579364
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
385000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
384000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
578284000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
567637000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2468000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3388000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-245943000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-218379000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
330258000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
346254000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
459563000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
479792000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3860000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1808000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
422000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14284000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9693000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16959000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8139000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
31243000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
17832000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-27383000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16024000
CY2022Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
218000
CY2021Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
15000
CY2022Q1 us-gaap Interest Expense
InterestExpense
818000
CY2021Q1 us-gaap Interest Expense
InterestExpense
522000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-600000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-507000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27983000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16531000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-419000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-340000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-27564000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16191000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29605143
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22100840
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-27564000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16191000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
920000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-58000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26644000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16249000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
346254000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
450000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10198000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
920000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-27564000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
330258000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
95460000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
284000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1800000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
58775000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3821000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-58000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16191000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
142091000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-27564000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-16191000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
10198000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3821000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
325000
CY2022Q1 bcyc Non Cash Interest Expense
NonCashInterestExpense
135000
CY2021Q1 bcyc Non Cash Interest Expense
NonCashInterestExpense
93000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-991000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3520000
CY2022Q1 bcyc Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
2774000
CY2021Q1 bcyc Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
2277000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1341000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
922000
CY2022Q1 bcyc Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-650000
CY2021Q1 bcyc Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
2434000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
748000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
353000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-255000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-304000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2337000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1858000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-105000
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
2466000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3850000
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
236000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
178000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
171000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26400000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13707000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4756000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
623000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4756000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-623000
CY2021Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
58775000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
450000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
284000
CY2021Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
15000000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
450000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
74059000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-603000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
182000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31309000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
59911000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
438680000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
135990000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
407371000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
195901000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
664000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
429000
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-35000
CY2022Q1 bcyc Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
375000
CY2021Q1 bcyc Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
199000
CY2022Q1 bcyc Purchase Of Property And Equipment Included In Accounts Payable Or Accrued Expenses
PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableOrAccruedExpenses
1630000
CY2021Q1 bcyc Purchase Of Property And Equipment Included In Accounts Payable Or Accrued Expenses
PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableOrAccruedExpenses
76000
CY2022Q1 bcyc Non Cash Impact Of Portway Lease Right Of Use Asset And Operating Lease Liabilities
NonCashImpactOfPortwayLeaseRightOfUseAssetAndOperatingLeaseLiabilities
3120000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
407400000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-27600000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16200000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-245900000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for research and development expenses, revenue recognition, share-based compensation expense, valuation of right-of-use assets and liabilities, and income taxes, including the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.</p>
CY2022Q1 bcyc Debt Instrument Prepayment Option Excess Of Outstanding Amount
DebtInstrumentPrepaymentOptionExcessOfOutstandingAmount
5000000.0
CY2022Q1 bcyc Reduction Of Research And Development Expense Related To Government Grant Arrangements
ReductionOfResearchAndDevelopmentExpenseRelatedToGovernmentGrantArrangements
400000
CY2021Q1 bcyc Reduction Of Research And Development Expense Related To Government Grant Arrangements
ReductionOfResearchAndDevelopmentExpenseRelatedToGovernmentGrantArrangements
1100000
CY2022Q1 us-gaap Grants Receivable
GrantsReceivable
2300000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
29873000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
100000000.0
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
100000000.0
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13831000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7923000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4982000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4800000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8849000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3123000
CY2022Q1 us-gaap Depreciation
Depreciation
400000
CY2021Q1 us-gaap Depreciation
Depreciation
300000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2670000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6429000
CY2022Q1 bcyc Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
5150000
CY2021Q4 bcyc Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
3980000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1065000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
882000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2996000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2383000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
384000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
570000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12265000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14244000
CY2022Q1 bcyc Debt Instrument End Of Term Charge Rate
DebtInstrumentEndOfTermChargeRate
0.050
CY2022Q1 bcyc Debt Instrument Additional Interest Rate Event Of Default
DebtInstrumentAdditionalInterestRateEventOfDefault
0.050
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2022Q1 bcyc Debt End Of Term Charge
DebtEndOfTermCharge
470000
CY2021Q4 bcyc Debt End Of Term Charge
DebtEndOfTermCharge
376000
CY2022Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
462000
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
503000
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
30008000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
31500000
CY2022Q1 bcyc Long Term Debt Including End Term Charge
LongTermDebtIncludingEndTermCharge
31500000
CY2022Q1 bcyc Number Of Voter Per Share
NumberOfVoterPerShare
1
CY2021Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2022Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
57070181
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
55295420
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10198000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3821000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3860000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1808000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
71340000
CY2022Q1 bcyc Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
0
CY2022Q1 bcyc Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
3860000
CY2022Q1 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-1902000
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
65578000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
35156000
CY2021 bcyc Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
49056000
CY2021 bcyc Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
11697000
CY2021 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-1175000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
71340000
CY2022Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2022Q1 bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
3819000
CY2021Q1 bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
1652000
CY2022Q1 bcyc Contract With Customer Liability Revenue Recognized Expiration Of Material Rights
ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
41000
CY2021Q1 bcyc Contract With Customer Liability Revenue Recognized On Changes In Transaction Price
ContractWithCustomerLiabilityRevenueRecognizedOnChangesInTransactionPrice
156000
CY2022Q1 bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
3860000
CY2021Q1 bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
1808000
CY2016Q4 bcyc Research And Development Arrangement Obligation To Repay Other Parties
ResearchAndDevelopmentArrangementObligationToRepayOtherParties
50900000
CY2019Q4 bcyc Research And Development Arrangement Obligation To Repay Other Parties
ResearchAndDevelopmentArrangementObligationToRepayOtherParties
60300000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-400000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-300000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
906000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
232000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
267000
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
80000
CY2022Q1 us-gaap Lease Cost
LeaseCost
1173000
CY2021Q1 us-gaap Lease Cost
LeaseCost
312000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y10M24D
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0704
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0793
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2999000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4245000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4267000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4289000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3441000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
821000
CY2022Q1 bcyc Present Value Adjustment For Operating Lease Payment
PresentValueAdjustmentForOperatingLeasePayment
2973000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17089000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2996000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14093000
CY2022Q1 bcyc Maximum Days Allowed For Cancellation Of Contracts Prior Written Notice
MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice
P90D
CY2022Q1 bcyc Period Of Royalty Payments Agreed Under Arrangement
PeriodOfRoyaltyPaymentsAgreedUnderArrangement
P10Y
CY2022Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27564000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16191000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29605143
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22100840
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5567066
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4950608
CY2022Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2022Q1 us-gaap Noncurrent Assets
NoncurrentAssets
25599000
CY2021Q4 us-gaap Noncurrent Assets
NoncurrentAssets
17789000

Files In Submission

Name View Source Status
0001558370-22-007223-index-headers.html Edgar Link pending
0001558370-22-007223-index.html Edgar Link pending
0001558370-22-007223.txt Edgar Link pending
0001558370-22-007223-xbrl.zip Edgar Link pending
bcyc-20220331.xsd Edgar Link pending
bcyc-20220331x10q.htm Edgar Link pending
bcyc-20220331x10q_htm.xml Edgar Link completed
bcyc-20220331xex31d1.htm Edgar Link pending
bcyc-20220331xex31d2.htm Edgar Link pending
bcyc-20220331xex32d1.htm Edgar Link pending
bcyc-20220331_cal.xml Edgar Link unprocessable
bcyc-20220331_def.xml Edgar Link unprocessable
bcyc-20220331_lab.xml Edgar Link unprocessable
bcyc-20220331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending